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Abstract
Purpose Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral 
nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin 
D1, osteopontin (OPN) and fibronectin (FN) correlate with the response to neo-adjuvant CHT (naCHT) in children with 
advanced inoperable MPNST.
Methods The study included 26 children with MPNST (M/F 14/12, median age 130 months) treated in Polish centers of 
pediatric oncology between 1992 and 2013. Tissue expression of markers was studied immunohistochemically in the manu-
ally performed tissue microarrays and assessed semi-quantitatively as low and high, based on the rate of positive cells and 
staining intensity.
Results Good response to naCHT was noted in 47.6%, while poor—in 52.4% of patients. The response to naCHT was 
influenced negatively by the presence of neurofibromatosis NF1 and high initial tumor tissue expression of OPN, survivin, 
p53 and cyclin D1. Patients with high tumor expression of either OPN, survivin or p53 and those with simultaneous high 
expression of ≥ 3 of the markers, responded significantly worse to naCHT, than patients, in whom expression of ≤ 2 markers 
were detected at diagnosis. Nearly, 85% of patients expressing ≥ 3 markers, responded poor to CHT; while 87.5% of children, 
expressing ≤ 2 markers, were good responders.
Conclusion The initial tumor tissue expression of OPN, survivin, p53 and cyclin D1 may serve as markers to predict response 
to naCHT in pediatric advanced MPNST. Future studies in more numerous group of patients are needed to confirm these 
preliminary results.
Keywords Survivin · P53 · Cyclin D1 · Osteopontin · Response to neo-adjuvant chemotherapy · Malignant peripheral nerve 
sheath tumor · Children
Introduction
Malignant peripheral nerve sheath tumors (MPNST) are rare 
soft tissue sarcomas (STS) of neurogenic origin. Most cases 
arise in adulthood, however, 10–20% of MPNST occur in 
the first decades of life. MPNST may arise from pre-existing 
neurofibromas, particularly in patients with neurofibroma-
tosis type 1 (NF1), or de novo (Ducatman et al. 1986). 
MPNST typically localize in the trunk, extremities and head 
and neck, with the majority of lesions being deep seated. 
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The mainstay of treatment of MPNST, both in children and 
adults, is complete surgical resection with negative margins.
However, most cases of MPNST are diagnosed in 
advanced stages with invasive and/or metastatic tumors, 
making complete surgery infeasible as a primary proce-
dure. Postoperative radiotherapy (RTX) is recommended 
for local control in patients in whom incomplete resection 
was performed. Nevertheless, the prognosis in such patients 
remains unsatisfactory—with the 5-year-overall survival 
(5-y-OS) rate of approximately 34–44% for children and 
adults (Ducatman et al. 1986).
The effectiveness of neo-adjuvant CHT (naCHT) in 
patients with initially inoperable MPNST is uncertain. Some 
authors have regarded MPNST as a chemoresistant malig-
nancy (Zehou et al. 2013; Kolberg et al. 2013). However, 
in pediatric MPNST, the post-CHT tumor regression was 
shown to enable complete delayed resections in a propor-
tion of patients, which, in turn, improved the outcome (Carli 
et al. 2005; Ferrari et al. 2011). This therapeutic strategy has 
been accepted and used in most protocols recommended for 
pediatric MPNST (Treuner et al.1991). Most authors report 
that the response to CHT is significantly worse in patients 
with NF1 (Ferrari et al. 2011). Additionally, the chemosen-
sitivity of MPNST cannot be predicted based on clinical 
features of the disease in particular patients. Therefore, it 
is important to define new markers reflecting the biological 
aggressiveness of MPNST, which might help to optimally 
select candidates most likely to benefit from intense naCHT.
Recent studies suggest that MPNST growth is a multi-
stage process that may involve a number of altered cell-cycle 
regulators. Among them, survivin, p53, and cyclin D1 have 
been associated with the deregulation of the cellular prolif-
eration and worse OS in sarcomas (Zhou et al. 2003). More-
over, the extracellular matrix (ECM) glycoproteins, such as: 
osteopontin (OPN) and fibronectin (FN), have been shown to 
facilitate tumor progression and metastasis of malignancies, 
including sarcomas (Ioachim et al. 2002; Weber et al. 2010).
Cell-cycle checkpoint regulator, survivin, is a protein 
minimally expressed in healthy tissues. As a member of the 
inhibitor of apoptosis protein (IAP) family, survivin regu-
lates cell division at G2 phase. Its accumulation interferes 
with the activation of caspase activity during programmed 
cell death and thus promotes cell growth (Brady et al. 2015). 
High expression of survivin has been correlated with poor 
clinical outcomes in various carcinomas, neuroblastoma (Ito 
et al. 2005), medulloblastoma (Fangusaro et al. 2005) and 
also with the chemoresistance in adult rhabdomyosarcoma 
(RMS) and MPNST (Caldas et al. 2006).
TP53 is a tumor suppressor gene, located on chromo-
some 17, responsible for modulating the function of pro-
teins that protect cells from apoptosis in response to stress 
(Partridge et al. 2007). It has been recently stated that 
TP53 mutations are present in 75% of MPNST tumors 
(Kindblom et al. 1995). Overexpression of p53 protein and 
mRNA were found in MPNST, as compared to benign neu-
rofibromas (Leroy et al. 2001). In addition, p53 reactivity 
was more frequent in NF1-associated MPNST (Zhou et al. 
2003). These findings may indicate that a p53-mediated 
pathway plays a role in the development and growth of 
MPNST (Cunha et al. 2012). A close relation between the 
regulation of p53 and survivin, reported in many adult 
carcinomas, supports the involvement of these markers in 
the processes of tumor cell apoptosis and survival (Sarela 
et al. 2002).
Cyclin D1 is a proto-oncogene, responsible for the activa-
tion of cyclin-dependent kinases which proceed to phospho-
rylate retinoblastoma (Rb) protein and activate transcription 
factors involved in the transition from G1 to S phase in the 
cell cycle (Cordon-Cardo et al. 1995). The overexpression 
and amplification of cyclin D1 contributes to tumor genesis 
and has been associated with poor prognosis of many can-
cers of adults, including: esophageal, colon, prostate, pan-
creas, and bladder cancers (Ikeguchi et al. 2001; Gansauge 
et al. 1997). The overexpression of cyclin D1 has been asso-
ciated with worse OS and higher tumor grade in STS of the 
extremities and retroperitoneum (Kim et al. 1998).
OPN and FN are important components of ECM, facilitat-
ing the growth of a variety of human cancers (Ioachim et al. 
2002; Weber et al. 2010). Both markers have been involved 
in the processes of cell adhesion and migration, blood coag-
ulation, host defenses, tumor invasion and early metastases. 
In cancer, OPN plays multifaceted roles in promoting the 
tumor progression by regulating cell–matrix interactions and 
cellular signaling, inhibiting apoptosis of tumor cells (Stan-
dal et al. 2004) and stimulating neo-angiogenesis (Anborgh 
et al. 2011). OPN overexpression has been linked to an unfa-
vorable prognosis in many adult malignancies, including sar-
comas (Bramwell et al. 2005). FN is produced by various 
types of benign and malignant epithelial and mesenchymal 
cells, being involved in a number of processes crucial to 
the tumors’ invasion and metastasis (Knowles et al. 2013). 
FN is an inducer and one of the markers of the cells’ mes-
enchymal phenotype, which is upregulated during the epi-
thelial–mesenchymal transition (EMT), through which the 
epithelial tumor cells achieve more aggressive phenotype 
and invasive properties. Several studies confirm the role of 
FN in the pathogenesis, invasiveness and lung metastases 
formation of adult RMS (Ito et al. 2004).
The overexpression of survivin, p53, cyclin D1, OPN and 
FN may reflect the inner biology of MPNST, with respect to 
cell proliferation, invasion and escape from apoptosis. In the 
present study, we investigated the role of tumor expression 
of survivin, p53, cyclin D1, OPN, and FN in the predic-
tion of the response to naCHT in children with advanced 
MPNST.
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Materials and methods
Patients’ characteristics
The study included 26 children with MPNST (14M/12F; 
age range, 2–252 months; median age, 130 months), reg-
istered in the Polish Pediatric STS Registry. All MPNST 
diagnoses were performed by pathologists from two 
independent institutions. For the purpose of this study, 
the tumor specimens were reviewed again by one of the 
authors (E.I-S.). The stages of MPNST were defined 
according to both clinical tumor nodes metastases (TNM) 
pre-treatment staging system and the Intergroup Rhabdo-
myosarcoma Study (IRS) post-surgical grouping system.
All children were treated between III’1992 and 
XI’2013, using a multi-modality therapeutic CWS (Coop-
erative Weichteilsarkom Study Group) protocols, includ-
ing surgery, CHT, and RTX. The surgical tumor resection 
performed as an initial measure was termed primary exci-
sion (PE). Microscopically complete surgery was termed 
R0 (IRS I), microscopically incomplete—R1 (IRS II), 
excision with macroscopic residues and biopsy only—R2 
(IRS III). IRS IV meant metastatic disease at diagnosis. 
RTX with the use of external beam irradiation was admin-
istered to patients considered at risk of local recurrence. 
Chemotherapeutic schemes did not change substantially 
over the years and comprised cycles composed mostly of: 
vincristine, ifosfamide, dactinomycin, anthracyclines (dox-
orubicin or epirubicin), etoposide and carboplatin. The 
combination of drugs depended on the risk group clas-
sification and response to initial CHT.
Response to naCHT was evaluated after three courses 
of CHT (between 9th and 10th weeks of treatment). It 
was based on the reduction in volume of all measurable 
lesions, using the following criteria: complete response 
(CR) = complete disappearance of disease; good response 
(GR)—tumor reduction ≥ 67% <100%; partial response 
(PR) = tumor reduction ≥ 33 < 67%; stable disease 
(SD) = tumor reduction < 33%; progression of disease 
(PD) = increase in tumor size or new lesion detection. 
“Good response” to CHT comprised CR, GR and PR, 
while SD and PD were termed “poor response” to CHT.
Immunohistochemical analysis of markers
The study was carried out in 26 archival histological sam-
ples of fresh-frozen paraffin-embedded (FFPE) primary, 
chemo-naive MPNST tumors, obtained at diagnosis of 
pediatric patients diagnosed and treated in Polish onco-
logic centers between 1992 and 2013. The samples were 
marked in a way preventing identification by other persons.
Pathological analyses and IHC testing were performed 
in the Department of Pathology and Neuropathology Medi-
cal University of Gdansk (MUG). From the representative 
sections, the tissue microarrays (TMA) was constructed, 
using the commercially available Tissue -Tek® Quick-Ray 
™ TMA System kit, of the Sakura Finetek USA, Inc. The 
IHC stainings were performed on TMA, using monoclonal 
antibodies to detect analyzed markers. The appropriate posi-
tive and negative controls were introduced. The qualitative 
and quantitative analysis of protein expression in MPNST 
tissue was performed using the digital image analyzer. The 
immunophenotyping was made by the visualization system 
Dako, Denmark.
The expressions of analyzed markers in FFPE tumors 
were assessed using a semiquantitative method, based on the 
intensity of color reaction (on a scale of + to +++), and the 
rate of immunopositive cells (within the ranges of 0–5, 6–25, 
26–50, > 50%). Based on these two variables, a numerical 
ratio of the markers’ expression was estimated and used 
for further analyses. Its value determined the expression of 
markers as low or high. Figure 1a–e shows the immunostain-
ings of the analyzed markers in MPNST samples.
The study was approved by the Independent Bioethical 
Committee of the MUG, Poland (No. NKBBN/449/2013).
Statistical analysis
The results were subjected to statistical study, using com-
puter statistical software package EPIINFO Ver. 7.1.1.14 
(02-07-2013). p < 0.05 was considered statistically 
significant.
Results
The clinical characteristics of the study group and the results 
of the tumor expressions of analyzed markers are presented 
in Table 1.
Over 80% (21/26) of patients were diagnosed in highly 
advanced stages of disease—inoperable (n = 16; IRS III) or 
metastatic (n = 5; IRS IV). The primary tumors were located 
in unfavorable sites, including: head and neck paramenin-
geal region, bladder and prostate, inner organs, retroperito-
neum, extremities and other in 24 (92%) patients. Most of 
the tumors were large (> 5 cm in 20 children, 77%; > 10 cm 
in 10 children, 38%), invasive (T2 feature) in 88% of patients 
and deeply seated (17 patients, 65%). In ten patients (38%), 
NF1 was diagnosed. The 5-year-event free survival (EFS) 
for the whole study group was 35.6 ± 9.7% and 5-y-OS—
62.2 ± 10.2%. Median EFS was 19.8 months and median 
OS was 51 months.
Response to naCHT was assessable in 21 children (81%). 
Five patients, who were not assessable, included: four 
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children with no macroscopic tumor residue after PE and 
one child after R2 PE, who died of complications soon after 
treatment introduction. Ten patients (47.6%) achieved good 
response to naCHT (CR in one, GR in one and PR in eight), 
while 11 patients (52.4%)—poor response to naCHT (SD 
in six and PD in five). The response to naCHT and prog-
nosis were significantly worse in NF1 patients. Among ten 
patients with NF1, only three achieved good response to 
naCHT. Within 16 patients without NF1 good response to 
naCHT was stated in 7 children (43.8%). All of them are 
alive and without evidence of disease (Table 2).
Markers analysis
The results of the IHC expressions of survivin, p53, cyclin 
D1, OPN, and FN in particular patients together with their 
clinical characteristics and outcome are displayed in Table 1. 
The comparison between the expressions of analyzed mark-
ers in good and poor responders are shown in Table 3.
The expression of particular markers in relation 
to the response to CHT
Survivin was expressed in 16/21 (76%) patients, OPN in 14 
(67%), FN in 13 (62%), cyclin D1 in 11 (52%) and p53 in 
11 (52%). Figure 1a–e shows various immunoreactivities 
of the analyzed markers in MPNST tumors. Additionally, 
significant positive correlations were found between cyclin 
D1 and p53 (p = 0.010), OPN and p53 (p = 0.023) and cyclin 
D1 and FN (p = 0.032).
Patients with poor response to naCHT demonstrated 
high expressions of analyzed markers more frequently than 
patients with good response to naCHT. In poor responders, 
survivin was expressed in all patients, OPN in 81.8%, cyc-
lin D1 in 72.7%, p53 in 81.8%, and FN in 81.8%. In good 
responders, the expression of analyzed markers was less 
frequent (50, 20, 50, 40 and 20%, respectively). All patients 
expressing negatively for survivin (n = 5) responded well to 
naCHT (CR-1, GR-1, PR-3). In the univariate analysis, it 
was shown that high expressions of survivin, p53, and OPN 
were significantly associated with a poor response to naCHT 
(p = 0.009, p = 0.012 and p = 0.018, respectively). The tumor 
expressions of cyclin D1 and of FN were found higher in 
poor responders, than in good responders, however, the dif-
ferences between the groups were insignificant (p = 0.086, 
p = 0.080, respectively).
The number of markers expressed simultaneously 
in relation to response to naCHT
Only one patient did not display any marker’s expression. 
This patient achieved PR to naCHT and was alive at the last 
observation, 16 months after therapy discontinuation. The 
expression of one marker was found in four patients, two 
markers—in three patients, three markers—in three, four 
markers—in four and all five markers in six patients. Among 
Fig. 1  The immunostaining of the analyzed markers in MPNST sam-
ples. a Low expression of survivin (×200). b The p53 strong immu-
noreactivity (×400). c High cyclin D nuclear staining (strong immu-
noreactivity in more than 50% of cells). d High diffuse nuclear and 
cytoplasmatic immunoreactivity of osteopontin (×200). e Fibronectin 
high expression in more than 90% cells (×200)
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Table 2  NF1 correlation to 
CHT response and outcome in 
selected patients
NF1 neurofibromatosis type 1; CR complete response; GR good response; PR partial response; SD stable 
disease; PD progression of disease; DOD died of disease; N/A no data; n patients number; (+), positive; 
(−), negative
NF 1 (+) NF 1 (−)
Alive Dead n Alive Dead n
Good response 
(CR + GR + PR)
1 2 3 7 0 7
Poor response (SD + PD) 1 4 5 4 2 6
N/A 1 1 2 2 1 3
Total 3 7 10 13 3 16
Table 3  The tumor expression 
of analyzed markers in poor and 
good responders with MPNST
OPN osteopontin, FN fibronectin, CHT chemotherapy, F Fisher’s test, (+) high immunostaining of the 
tumor tissue, (−) low immunostaining of the tumor tissue
High markers’ expression in tumor n Good response 
to CHT
Poor response 
to CHT
p
P53 (+) 11 2 9 0.00892F
P53 (−) 10 8 2
OPN (+) 14 5 9 0.0183F
OPN (−) 7 5 2
Survivin (+) 16 5 11 0.0124F
Survivin (−) 5 5 0
FN (+) 13 4 9 0.0805F
FN (−) 8 6 2
Cyclin D1 (+) 11 3 8 0.0861F
Cyclin D1 (−) 10 7 3
Survivin (+) and cyclin D1 (+) 11 3 8 0.0256F
Both (−) 5 5 0
p53 (+) and cyclin D1 (+) 8 1 7 0.0101
Both (−) 7 6 1
OPN (+) and cyclin D1 (+) 10 2 8 0.118F
Both (−) 6 4 2
Survivin (+) and OPN (+) 13 4 9 –
Both (−) 4 4 0
Survivin (+) and p53 (+) 10 1 9 –
Both (−) 4 4 0
Survivin (+) and FN (+) 10 1 9 –
Both (−) 2 2 0
OPN (+) and p53 (+) 9 1 8 0.0230
Both (−) 5 4 1
OPN (+) and FN (+) 8 0 8 –
Both (−) 2 1 1
OPN (+) and p53 (+) and cyclin D1 (+) 9 1 8 0.00548
Both (−) 10 8 2
Survivin (+) and OPN (+) and p53 (+) 9 1 8 0.00874
Maximum 1 marker (+) 7 6 1
OPN (+) and survivin (+) and cyclin D1 (+) 10 2 8 0.0584F
Maximum 1 marker (+) 7 5 2
OPN and survivin and p53 and cyclin D1—at 
least 3 of 4 markers (+)
11 2 9 0.00892F
Maximum 2 markers (+) 10 8 2
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four children, who expressed only one marker (patients 14, 
16, 18 and 19), two achieved PR, one CR and one SD. All 
these children survived. The only patient in our study to 
achieve CR was found to express FN alone.
Among 13 patients, who expressed three or more mark-
ers, 11 children (84.6%) responded poor to naCHT and 
only two (15.4%) achieved PR to naCHT. To the contrary, 
among eight children expressing no more than two mark-
ers, there were seven good responders (87.5%) and only one 
poor responder (SD, 12.5%). Six children, who expressed 
all five analyzed markers, had poor response to naCHT. To 
the contrary, four of five patients who did not express any of 
the markers or expressed only one marker, responded well 
to naCHT.
It was observed that simultaneous high expression of 
particular markers in one tumor sample was associated 
with worse response to naCHT (Table 3). For example, 
the majority of patients expressing positively for both sur-
vivin and cyclin D1 (8/11, 73%) responded poor to naCHT, 
while five patients with no expression of these two markers 
responded well. The difference between these two groups 
reached statistical significance (p = 0.026). Similarly, poor 
response to CHT was significantly more frequent in chil-
dren with MPNST with simultaneous high expressions of 
p53 and cyclin D1, and of OPN and p53, in comparison 
to patients not expressing any of these markers (p = 0.010; 
p = 0.023; respectively). Due to low number of cases, it 
was impossible to assess the statistical difference between 
subgroups of patients with and without high expressions of 
survivin and OPN, survivin and p53, survivin and FN, and 
OPN and FN. However, in all subgroups of patients with 
high expressions of these pairs of markers, poor response to 
naCHT predominated. It was noted that simultaneous high 
expressions of OPN, p53 and cyclin D1 was significantly 
more common in poor responders than no expression of the 
markers (p = 0.005). In addition, high simultaneous expres-
sions of survivin, OPN and p53 were associated with sig-
nificantly worse response to naCHT, than high expression 
of a maximum one of these markers (p = 0.009). Patients, in 
whom high tumor tissue immunoreactivity towards OPN, 
survivin, p53 and cyclin D1, or just three of the four mark-
ers were stated at diagnosis, responded significantly worse 
to CHT than patients, who expressed no more than two of 
these markers (p = 0.009).
Discussion
The aim of the study was to assess whether selected 
proteins regulating the cell-cycle, tumor cells apoptosis 
and tumor invasion, i.e.: survivin, p53, cyclin D1, OPN 
and FN, may become potential biomarkers to predict 
the response to naCHT in advanced pediatric MPNST. 
Identification of such biomarkers would allow for more 
individualized treatment based on optimal selection of 
candidates for multidrug naCHT. This would diminish the 
risk of unnecessary CHT-related complications in those, 
who are not likely to benefit from CHT.
It is indisputable that complete surgical tumor excision 
with negative (wide) margins offers the best outcome, 
both in children and adults (Carli et al. 2005; Ferrari et al. 
2011). However, in the majority of children with MPNST, 
the disease is diagnosed late, in the phase of invasive, 
inoperable and/or metastatic tumor, which is not feasi-
ble for the upfront complete resection. In such cases, the 
CWS protocols recommend the naCHT, aimed to shrink 
the tumor preoperatively. The chemotherapeutic courses 
administered to children with stage III and IV MPNST, 
reported in our study, did not change substantially over the 
years of analysis. In patients with MPNST stage III, most 
commonly VAIA III regimen was administered, including 
the alternating courses, containing ifosfamide, vincristine, 
dactinomycin (I2VA) or ifosfamide, vincristine and doxo-
rubicin (I2VAdr). Children with stage IV MPNST received 
the CEVAIE regimen, composed of I3VAdr, (ifosfamide, 
vincristine and doxorubicin), CEV (carboplatin, vincris-
tine and epirubicin) and I3VE (ifosfamide, vincristine and 
etoposide) courses.
The rate of good responses to naCHT among 21 evaluable 
patients, was 48%. This was similar to the results of Carli 
et al., who reported responses to CHT in 45% of children (30 
out of 64 evaluable). However, in their study, much better 
outcome was noted in patients treated with naCHT-contain-
ing ifosfamide (VAIA, IVA, CEVAIE, 65%), than in those 
receiving regimens including cyclophosphamide (VACA, 
VAC/CAV, 17%) or cisplatin and etoposide (20%) (Carli 
et al. 2005). In our series, all patients with stage III and IV 
received naCHT-containing ifosfamide. The cumulative dose 
of ifosfamide during the first-line treatment of both stage III 
and stage IV MPNST was 54 g/m2.
In clinical practice, it is difficult to predict, who will ben-
efit from naCHT, and in whom this treatment is of no value. 
Analysis of clinical markers, such as: tumor size, location, 
invasiveness, lymph node involvement and presence of 
metastases, does not help to predict the chemosensitivity of 
MPNST. However, most literature data report on the worse 
response to naCHT in NF1-related MPNST, as compared 
to sporadic cases (Ferrari et al. 2011). In the Italian and 
German series of 167 consecutive pediatric patients with 
MPNST, recruited over a 25-year period, the response to 
naCHT was found 18% NF-1 positive and 55% in NF1(-) 
patients (Carli et al. 2005). Similarly, in our material, the 
response to naCHT and survival rates were significantly 
negatively influenced by the presence of NF1. Additionally, 
in our series, the rate of NF1(+) patients was higher than in 
the study reported by Cari et al. (38% vs. 11%), which might 
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have caused worse response to naCHT, even if all patients 
received ifosfamide-containing course.
The molecular mechanisms responsible for the progres-
sion and resistance to naCHT in sporadic or NF1-associated 
MPNST, are largely unknown. Biallelic NF1 gene inactiva-
tion is not enough for progression toward MPNST, and addi-
tional genetic alterations are necessary (Sohier et al. 2017). 
They are thought to involve the factors regulating the tumor 
cell-cycle, apoptosis and invasion (Levy et al. 2004). Recent 
publications have suggested that the cell-cycle pathway and 
its multiple protein components, including survivin, cyclin 
D1 and p53, are frequently altered in cancer. In addition, 
ECM proteins, OPN and FN, were shown to play important 
roles in cancers’ invasion, neoagiogenesis, metastasis and 
progression. The impact of these markers on the response to 
naCHT in childhood MPNST has not been evaluated so far.
In the present study, we found that all analyzed tumor 
markers were expressed in at least half of the samples of 
primary chemo-naive MPNST tumors. High expressions of 
survivin and OPN were detected most commonly, in 76 and 
67% of cases, respectively. Many neoplasms, including car-
cinomas of breast, prostate, lung, colon, bladder, esophagus, 
as well as lymphomas, neuroblastomas and osteosarcomas, 
were previously shown to overexpress survivin (Tanaka et al. 
2000; Xing et al. 2001; Kato et al. 2001). High expression of 
survivin was also reported in over 80% of RMS tumors, the 
most common subtype of pediatric STS. The exact role of 
this protein in pathogenesis and invasion of STS is not clear, 
however, survivin expression was suggested to predominate 
in more aggressive and invasive tumors (Fangusaro et al. 
2005). Alaggio et al. reported that high expression of sur-
vivin mRNA correlated with shorter survival and more 
aggressive clinical behavior of adult MPNST (Alaggio et al. 
2013).
Due to the rarity of STS, the data on the prognostic role 
of OPN in these tumors are limited. However, Bramwell 
et al. have shown that benign mesenchymal tumors, such as 
lipomas, borderline-malignant dermatofibrosarcomas and 
well-differentiated/myxoid liposarcomas do not express 
OPN, while other subtypes of malignant STS of histologi-
cal grades 2 or 3, display strong expression of OPN in over 
80% of samples (Bramwell et al. 2005). High tumor OPN 
expression was reported to correlate with higher grade, stage 
and shorter relapse-free survival and overall survival in adult 
STS (Bache et al. 2010). In pediatric cancers, the tumor 
expression of OPN was examined in leukemias, lymphomas, 
Langerhans cell histiocytosis, central nervous system (CNS) 
tumors, osteosarcoma and renal tumors (summarized by 
Karpinsky et al. 2017). To date, there has been no study on 
the prognostic role of this marker in children with MPNST 
or other STS subtypes.
Our study was the first to determine whether pre-treat-
ment tumor expressions of survivin, p53, cyclin D1, OPN 
and FN might help to predict the response to naCHT in 
pediatric inoperable and/or metastatic MPNST. It appeared 
that all analyzed markers were more frequently expressed 
in poor responders to naCHT, than in good responders. 
Survivin was expressed in all, OPN, p53 and FN—in 
81.8% each, and cyclin D1 in 72.7% of tumor samples 
obtained from patients, who responded poor to naCHT. 
In good responders, the tumor expressions of particu-
lar markers were less frequent (50, 20, 40, 20 and 50%, 
respectively). It was found in univariate analysis, that 
high tumor expressions of survivin, p53, and OPN cor-
related significantly with poor response to naCHT. The 
tumor expressions of cyclin D1 and of FN were also higher 
in poor responders, than in good responders, however, 
the differences between the groups were insignificant. 
Our findings suggest that overexpression of the markers 
involved in tumor cells apoptosis, cell-cycle regulation and 
cancer invasiveness, may contribute to the resistance to 
CHT in childhood MPNST.
The influence of survivin, an anti-apoptotic protein, on 
the response to CHT and RTX is uncertain. In head and 
neck cancer, higher tumor survivin expression was asso-
ciated with a better response to RTX and longer survival. 
Accordingly, survivin silencing in cell lines led to decreased 
sensitivity to radiation (Farnebo et al. 2013). To the contrary, 
in the cancers of esophagus, breast and kidney, high IHC 
expression of survivin was correlated with a poor response 
to RTX (Jha et al. 2011). Additionally, inhibition of survivin 
was shown to sensitize tumor cells to different chemothera-
peutic agents, including cisplatin (Zaffaroni and Daidone 
2002). In our study, all poor responders were found to over-
express survivin while all five patients expressing negatively 
for survivin, responded well to naCHT (Table 3).
It has been suggested that treatment sensitivity of can-
cers is influenced by the altered function of p53 protein, 
resulting from the mutations of the TP53 tumor suppressor 
gene (Shukla et al. 2013). In NF1-related MPNST, the loss 
or mutation in the TP53 gene has been associated with an 
increased proliferative potential, formation of metastases 
and particularly poor prognosis (Upadhyaya et al. 1997). 
Brekke et al. have shown that patients with NF1-associated 
MPNST, in whom the accumulation of nuclear p53 was 
found, form a high-risk subgroup requiring adjuvant treat-
ment, even when in complete remission (Brekke et al. 2009). 
In our study, 8 of 10 patients with low tumor p53 expression 
responded well to naCHT, while 9 of 11 children with high 
p53 immunoreactivity responded poor.
Our review of all publications on the role of OPN in 
cancers of children and young adults has shown that the 
monitoring of OPN protein level in serum and cerebral-
spinal fluid of children with acute lyphoblastic ane-
mia with CNS involvement and in patients with highly 
malignant brain tumors, reflected the tumor bulk and the 
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response to CHT (Karpinsky et al. 2017). To date, there 
have been no publications on the impact of OPN expres-
sion on response to naCHT in patients with STS. In our 
series of children with MPNST, five of seven patients with 
low OPN expression responded well to naCHT.
Cyclin D1 has been frequently found deregulated in 
cancer and is regarded as a biomarker of invasive can-
cer phenotype. It has been also shown to influence the 
response to CHT and RTX (Shintani et al. 2001). Fol-
lowing exposure to environmental stress or DNA dam-
age, the rapid degradation of cyclin D1 ensures rapid cell 
cycle arrest (Yang et al. 2006). Several therapeutic agents 
have been shown to induce cyclin D1 degradation (Feng 
et al. 2007). The cyclin D1 accumulation and overexpres-
sion has led to increased chemotherapeutic resistance and 
protection from apoptosis (Shintani et al. 2002). Patients 
with head and neck squamous cell carcinomas (HNSCC) 
with high cyclin D1 tumor expressions were less likely to 
respond to neo-adjuvant cisplatin-based CHT and survive, 
than patients with low expressions of the marker (58 vs. 
85%; p < 0.001). It was concluded that tumor expression 
of cyclin D1 may serve as a predictive biomarker in select-
ing patients with HNSCC, who may benefit from naCHT 
(Feng et al. 2011). Several studies have also demonstrated 
abnormalities of both the p53 and the Rb1-cyclin D1 path-
ways in MPNST (Kourea et al. 1999).
The processes of the cell-cycle regulation, tumor cells’ 
proliferation and invasion, inhibition of apoptosis and 
promotion of neo-angiogenesis, mediated within tumor 
microenvironment by survivin, p53, cyclin D1, OPN and 
FN, are frequently interdependent. Moreover, these factors 
have been found to share mutual mechanisms and signal-
ing pathways. Not surprisingly, we have found significant 
positive correlations between p53 and cyclin D1, OPN and 
p53 and cyclin D1 and FN. Understandably, poor response 
to naCHT was significantly more frequent in children with 
simultaneous high expression of p53 and cyclin D1 and 
OPN and p53 and also of survivin and cyclin D1, in com-
parison to patients not expressing any of these markers. 
Simultaneous high expressions of OPN, p53 and cyclin D1 
were found significantly more frequently in poor respond-
ers, than no expression of these markers (p = 0.005). Gen-
erally, the more markers were expressed simultaneously 
in a tumor tissue, the worse was the response to naCHT. 
Patients expressing all five markers responded poor to 
CHT, while four of five patients with no markers or only 
one marker expressed—responded well to CHT. Interest-
ingly, the tumor expression of FN, either alone, or together 
with other markers, did not correlate with the response to 
naCHT in children with MPNST. Several previous stud-
ies have confirmed the role of FN in the pathogenesis of 
RMS and the invasiveness of adults RMS FN has been also 
suggested to be essential for lung metastasis in STS (Ito 
et al. 2004). However, FN determination at diagnosis in 
chemo-naive tumor samples of pediatric MPNST did not 
add significant prognostic information.
Conclusions
1. The response to naCHT in advanced pediatric MPNST 
is influenced by the NF1 status and initial tumor tissue 
expression of OPN, survivin, p53 and cyclin D1.
2. Patients with high tumor expression of either OPN, 
survivin or p53 and those with simultaneous high 
expression of ≥ 3 of the analyzed markers, responded 
significantly worse to naCHT, than patients, in whom 
expression of ≤ 2 markers were detected at diagnosis.
3. The role of FN in predicting response to naCHT—as a 
sole analyzed marker and together with others—was not 
confirmed.
4. Future studies in more numerous groups of patients are 
needed to confirm these preliminary results.
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